Rhumbline Advisers Reduces Stock Holdings in Integer Holdings Co. (NYSE:ITGR)

Rhumbline Advisers reduced its stake in shares of Integer Holdings Co. (NYSE:ITGR) by 0.7% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 95,282 shares of the medical equipment provider’s stock after selling 684 shares during the quarter. Rhumbline Advisers’ holdings in Integer were worth $12,627,000 as of its most recent filing with the SEC.

Other hedge funds have also modified their holdings of the company. Loomis Sayles & Co. L P raised its holdings in shares of Integer by 3.0% during the 3rd quarter. Loomis Sayles & Co. L P now owns 538,027 shares of the medical equipment provider’s stock valued at $69,943,000 after buying an additional 15,446 shares during the period. Jane Street Group LLC raised its holdings in shares of Integer by 23.3% during the 3rd quarter. Jane Street Group LLC now owns 151,397 shares of the medical equipment provider’s stock valued at $19,682,000 after buying an additional 28,572 shares during the period. Verition Fund Management LLC raised its holdings in shares of Integer by 17.4% during the 3rd quarter. Verition Fund Management LLC now owns 3,470 shares of the medical equipment provider’s stock valued at $451,000 after buying an additional 515 shares during the period. Versant Capital Management Inc raised its holdings in shares of Integer by 98.4% during the 4th quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider’s stock valued at $49,000 after buying an additional 183 shares during the period. Finally, KBC Group NV grew its stake in Integer by 83.3% during the 4th quarter. KBC Group NV now owns 1,598 shares of the medical equipment provider’s stock valued at $212,000 after purchasing an additional 726 shares in the last quarter. 99.29% of the stock is currently owned by hedge funds and other institutional investors.

Integer Price Performance

Shares of ITGR opened at $129.96 on Monday. Integer Holdings Co. has a 52 week low of $98.63 and a 52 week high of $146.36. The firm has a market cap of $4.37 billion, a price-to-earnings ratio of 38.68, a PEG ratio of 1.72 and a beta of 1.13. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. The stock has a 50 day moving average of $137.74 and a 200-day moving average of $132.58.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The company had revenue of $449.50 million for the quarter, compared to analyst estimates of $446.28 million. As a group, analysts forecast that Integer Holdings Co. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on ITGR shares. Wells Fargo & Company restated an “overweight” rating and set a $160.00 price objective on shares of Integer in a research note on Tuesday, December 3rd. Benchmark raised their price objective on Integer from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Friday. Oppenheimer lowered Integer from an “outperform” rating to a “market perform” rating in a research note on Friday. Citigroup raised their price objective on Integer from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, December 11th. Finally, KeyCorp raised their price objective on Integer from $144.00 to $154.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Integer presently has an average rating of “Moderate Buy” and a consensus target price of $147.67.

About Integer

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.